Lupin unveils Ganirelix Acetate Injection in US

Mumbai: Global pharma major Lupin Limited has announced
the launch of Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe, after having
received an approval from the United States Food and Drug Administration (U.S. FDA).

Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe is a generic equivalent to
the reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC.
It
is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing
controlled ovarian hyperstimulation.
Ganirelix Acetate Injection had estimated annual sales of USD 87 million in the U.S. (IQVIA MAT
December 2023).
Read also: Submit Animal Toxicity Study Report: CDSCO Panel Tells Lupin on Parkinsonism FDC drug
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The
Company develops and commercializes a wide range of branded and generic formulations, biotechnology
products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin
America (LATAM), Europe, and Middle East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has
a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s
health areas. The company
invested 7.9% of its revenue in research and development in FY23.
Lupin has 15 manufacturing sites, 7 research centers.
Read also: Lupin unveils Bromfenac Ophthalmic Solution, 0.075% in US
Facebook Comments